About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 1NCT00525447

Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma

This is a Phase I, open-label, multi-dose trial to define the MTD and tolerability of a regimen including lenalidomide, dexamethasone, and intravenous SGN-40 in patients with relapsed multiple myeloma...

Lead sponsor: Seagen Inc.•9 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Seagen Inc.

Collaborators

Genentech, Inc.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Diagnosis of multiple myeloma.
•Received at least one prior systemic therapy other than single-agent corticosteroids.
•Measurable disease of monoclonal protein greater than or equal to 0.5 gram/dL in plasma or 0.5 gram/24 hr urine collection, or greater than 10 mg/dL free light chain (FLC) in serum as determined by serum FLC assay and provided the serum FLC ratio is abnormal.

Exclusion Criteria

•Received an allogenic stem cell transplant.
•Previous intolerance of lenalidomide or dexamethasone.
•Primary invasive malignancy (other than multiple myeloma) within the last 3 years.

Related studies

A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy

NCT07249528 · Non-hodgkin Lymphoma, Multiple Myeloma

RECRUITINGPhase 1

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

NCT06215118 · Multiple Myeloma

RECRUITINGPhase 3

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

NCT06679101 · Multiple Myeloma, Newly Diagnosed Multiple Myeloma

RECRUITINGPhase 2

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

NCT05969860 · Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, and more

Promoting Diagnosis and Management of AL in Italy (ProDigALIty)

NCT06383143 · AL Amyloidosis, Smoldering Multiple Myeloma, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 9, 2014Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment36

Start dateAug 2007

Last updatedOct 9, 2014

Condition

Multiple Myeloma

Locations shown

Rocky Mountain Cancer Center

Denver, Colorado

H. Lee Moffitt Cancer Center & Research Institute

Tampa, Florida

Dana Farber Cancer Institute

Boston, Massachusetts

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 9, 2014Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions